Rochester, NJ, United States of America

Barbara B Lussier

This inventor holds 1 USPTO granted patent. Top assignee: Sterling Drug Inc.. Active years: 1993.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 1993

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Barbara B Lussier: Innovator in Immunomodulating Compounds

Introduction

Barbara B Lussier is a notable inventor based in Rochester, NJ (US). She has made significant contributions to the field of immunology through her innovative work on multiply substituted anilines, phenols, and pyridines. Her research focuses on compounds that mimic IL-1 activity, which is crucial for inducing IL-2 synthesis and subsequent IL-2 receptor expression.

Latest Patents

Barbara B Lussier holds a patent for her invention titled "Multiply substituted anilines, phenols and pyridines-immunomodulating." This patent provides compounds that are essential for advancing immunological therapies. The invention includes certain multiply substituted anilines, phenols, and pyridines, along with their pharmaceutically acceptable salts, which are designed to enhance immune responses.

Career Highlights

Throughout her career, Barbara has worked with Sterling Drug Inc., where she has been able to apply her expertise in developing innovative pharmaceutical solutions. Her work has contributed to the advancement of immunomodulatory therapies, showcasing her commitment to improving health outcomes.

Collaborations

Barbara has collaborated with esteemed colleagues, including Lee H Latimer and Carl R Illig. These partnerships have allowed her to expand her research and contribute to significant advancements in her field.

Conclusion

Barbara B Lussier's contributions to immunology through her innovative patents and collaborations highlight her role as a leading inventor in the pharmaceutical industry. Her work continues to influence the development of new therapies that can enhance immune function.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…